Skip to content
OpenCapital
Get started

Ardelyx ARDX Available For Sale Securities Debt Securities Current

Available For Sale Securities Debt Securities Current at other companies

Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
——
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
——

Other financials

Income statement

See full
Revenue$94.5M+27.5%
Gross profit$89.7M+45.1%
Operating income-$32.8M+9.8%
Net income-$37.6M+8.6%
EPS (diluted)-$0.15+11.8%

Balance sheet

See full
Cash & equivalents$31.2M+1.3%
Total debt$208.3M+34.3%
Total equity$148.6M+2.0%
Total assets$504.5M+23.0%

Cash flow

See full
Operating cash flow-$32.2M+16.2%
CapEx$69.0K-78.8%
Free cash flow-$32.3M+16.7%

Valuation

See full
Market cap$1.53B+79.5%
Enterprise value$1.71B+74.8%
P/S3.6×+1.2×

Profitability

See full
Gross margin92.5%+7.9pp
Operating margin-25.4%—
Net margin-13.6%—
FCF margin-40.9%—

Returns & leverage

See full
Return on equity-39.5%—
Debt / equity1.4×+0.3×
Current ratio3.5×-0.6×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The official record: Ardelyx’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ardelyx's available for sale securities debt securities current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ardelyx's available for sale securities debt securities current?
Ardelyx (ARDX) reported available for sale securities debt securities current of $206.87M in Q1 2026.
How has Ardelyx's available for sale securities debt securities current changed year-over-year?
Ardelyx's available for sale securities debt securities current increased by 13.0% year-over-year, from $183.14M to $206.87M.
What is the long-term trend for Ardelyx's available for sale securities debt securities current?
Over 5 years (2020 to 2025), Ardelyx's available for sale securities debt securities current has grown at a 15.6% compound annual growth rate (CAGR), from $95.45M to $196.69M.